Science Explorer Back to mapMap
Discussion
Company · Newton · United States

Siamab Therapeutics (United States)

Research works
8
▼ 96% vs 2018-21
Citations
91
11.6 per fractional work
Top-10% rate
4.8%
all institutions 10.0%
Open access
26%
world 40%
International
6%
world 18%

Not ranked overall: Siamab Therapeutics (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Siamab Therapeutics (United States) work in?

In all years, 69% of research at Siamab Therapeutics (United States) is in Life Sciences, 29% in Health Sciences. Its largest fields are Biochemistry, Genetics and Molecular Biology (61%), Medicine (29%), Immunology and Microbiology (7%). It does 2.0× the world's share of Life Sciences.

Life Sciences69%Physical Sciences2%Health Sciences29%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 4 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology561.4%
    2. Immunology and Microbiology17.4%
    1. Medicine229.1%
    1. Chemistry02.2%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Who are the top researchers at Siamab Therapeutics (United States)?

Ranked on the quality score, Jeff Behrens, David A. Eavarone and Jillian M. Prendergast lead among researchers whose main affiliation is Siamab Therapeutics (United States).

  1. 1 Jeff Behrens United States · #1,786,033 worldwide 313 citations · 18 works
  2. 2 David A. Eavarone United States · #2,012,717 worldwide 1.3k citations · 19 works
  3. 3 Jillian M. Prendergast United States · #2,207,843 worldwide 518 citations · 30 works
All ranked researchers at Siamab Therapeutics (United States)

What are the most cited papers from Siamab Therapeutics (United States)?

The most cited paper from Siamab Therapeutics (United States) is "Ovarian cancer stem cells: What progress have we made?" (Linah Al-Alem, Unnati M. Pandya, Andrew T. Baker et al., 2018), with 89 citations. Next come "Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity" (89) and "Humanized anti-Sialyl-Tn antibodies for the treatment of ovarian carcinoma" (54).

Most cited papers
#PaperReleasedCitations
1 Ovarian cancer stem cells: What progress have we made? Linah Al-Alem, Unnati M. Pandya, Andrew T. Baker et al. · The International Journal of Biochemistry & Cell Biology 17 Dec 2018 89
2 Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity Jillian M. Prendergast, Ana Paula Galvao da Silva, David A. Eavarone et al. · mAbs Open access 22 Feb 2017 89
3 Humanized anti-Sialyl-Tn antibodies for the treatment of ovarian carcinoma David A. Eavarone, Linah Al-Alem, Alexey A. Lugovskoy et al. · PLoS ONE Open access 27 Jul 2018 54
4 Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen, Sialyl-Thomsen-nouveau Kristen D. Starbuck, Linah Al-Alem, David A. Eavarone et al. · Oncotarget Open access May 2018 42
5 The novel anti-androgen candidate galeterone targets deubiquitinating enzymes, USP12 and USP46, to control prostate cancer growth and survival Urszula Lucja McClurg, Mahsa Azizyan, Daniel T. Dransfield et al. · Oncotarget Open access 18 May 2018 33
All 7 most cited papers, with filters and sorting

Which research topics does Siamab Therapeutics (United States) publish most on?

By volume in 2022-now: Immunotherapy and Immune Responses, Wnt/β-catenin signaling in development and cancer, Sarcoma Diagnosis and Treatment and Cytokine Signaling Pathways and Interactions.

  1. 1 Immunotherapy and Immune Responses Immunology 0 works
  2. 2 Wnt/β-catenin signaling in development and cancer Molecular Biology 0 works
  3. 3 Sarcoma Diagnosis and Treatment Pulmonary and Respiratory Medicine 0 works
  4. 4 Cytokine Signaling Pathways and Interactions Oncology 0 works
  5. 5 Cell Adhesion Molecules Research Immunology and Allergy 0 works
  6. 6 Glycosylation and Glycoproteins Research Molecular Biology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available25.5%not open74.5%

World: 40% of research is openly available.

with international co-authors6.4%domestic only93.6%

World: 18% is written across borders.

How has Siamab Therapeutics (United States)'s research output changed?

Output in 2022-2025 was 96% lower than in 2018-2021.

still counting20202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Newton

All research institutions in Newton

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Siamab Therapeutics (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.